These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37666293)

  • 1. Gemcitabine effects on tumor microenvironment of pancreatic ductal adenocarcinoma: Special focus on resistance mechanisms and metronomic therapies.
    Natu J; Nagaraju GP
    Cancer Lett; 2023 Oct; 573():216382. PubMed ID: 37666293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
    Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
    Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
    Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
    Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
    Liu Y; Li F; Gao F; Xing L; Qin P; Liang X; Zhang J; Qiao X; Lin L; Zhao Q; Du L
    Tumour Biol; 2016 Nov; 37(11):15283-15291. PubMed ID: 27696296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Binenbaum Y; Na'ara S; Gil Z
    Drug Resist Updat; 2015 Nov; 23():55-68. PubMed ID: 26690340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
    Cham KK; Baker JH; Takhar KS; Flexman JA; Wong MQ; Owen DA; Yung A; Kozlowski P; Reinsberg SA; Chu EM; Chang CW; Buczkowski AK; Chung SW; Scudamore CH; Minchinton AI; Yapp DT; Ng SS
    Br J Cancer; 2010 Jun; 103(1):52-60. PubMed ID: 20531411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
    Tu Q; Liu X; Yao X; Li R; Liu G; Jiang H; Li K; Chen Q; Huang X; Chang Q; Xu G; Zhu H; Shi P; Zhao B
    J Exp Clin Cancer Res; 2022 Sep; 41(1):274. PubMed ID: 36109793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
    Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
    Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
    Luo W; Yang G; Qiu J; Luan J; Zhang Y; You L; Feng M; Zhao F; Liu Y; Cao Z; Zheng L; Zhang T; Zhao Y
    Cancer Med; 2019 Oct; 8(14):6403-6413. PubMed ID: 31475468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
    Tarannum M; Vivero-Escoto JL
    Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
    Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B
    Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
    Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
    J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
    Ju HQ; Li H; Tian T; Lu YX; Bai L; Chen LZ; Sheng H; Mo HY; Zeng JB; Deng W; Chiao PJ; Xu RH
    J Pineal Res; 2016 Jan; 60(1):27-38. PubMed ID: 26445000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency.
    Chen D; Zhu X; Tao W; Kong Y; Huag Y; Zhang Y; Liu R; Jiang L; Tang Y; Yu H; Hao Q; Yang X; Zou H; Chen J; Lu Y; Zhang H; Li W
    J Control Release; 2020 Aug; 324():545-559. PubMed ID: 32504777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.